Ascletis announces favorable and differentiated pharmacokinetic profile of asc30 oral once-daily tablet in its u.s. phase ib multiple ascending dose study

-          asc30 oral once-daily tablet demonstrated approximately 2.3- fold  to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison . -          higher drug exposure and favorable tolerability profile positions asc30 oral once-daily tablet favorably compared to orforglipron.
ASC Ratings Summary
ASC Quant Ranking